It was reported that MT1 agonists could have a positive impact in reducing amyloidogenesis, and BACE1 activity as well as the cognitive impairment induced by LPS (Panmanee et al. 2015; Sun et al. 2020). This evidence concerns the gene BACE1 and Cognitive impairment.